Active Pharmaceutical Ingredients CDMO Market (By Product: Traditional Active Pharmaceutical Ingredient, Highly Potent Active Pharmaceutical Ingredient, Antibody Drug Conjugate, Others; By Synthesis: Synthetic, Biotech; By Drug: Innovative, Generics; By Workflow: Clinical, Commercial; By Application: Oncology, Hormonal, Glaucoma, Cardiovascular, Diabetes, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Active Pharmaceutical Ingredients CDMO Market, By Product

7.1.  Active Pharmaceutical Ingredients CDMO Market, by Product, 2020-2030

7.1.1.    Traditional Active Pharmaceutical Ingredient (Traditional API)

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    Highly Potent Active Pharmaceutical Ingredient (HP-API)

7.1.2.1.        Market Revenue and Forecast (2016-2030)

7.1.3.    Antibody Drug Conjugate (ADC)

7.1.3.1.        Market Revenue and Forecast (2016-2030)

7.1.4.    Others

7.1.4.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Active Pharmaceutical Ingredients CDMO Market, By Synthesis

8.1.  Active Pharmaceutical Ingredients CDMO Market, by Synthesis, 2020-2030

8.1.1.    Synthetic

8.1.1.1.        Market Revenue and Forecast (2016-2030)

8.1.2.    Biotech

8.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 9.  Global Active Pharmaceutical Ingredients CDMO Market, By Drug

9.1.  Active Pharmaceutical Ingredients CDMO Market, by Drug, 2020-2030

9.1.1.    Innovative

9.1.1.1.        Market Revenue and Forecast (2016-2030)

9.1.2.    Generics

9.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 10.      Global Active Pharmaceutical Ingredients CDMO Market, By Workflow

10.1.        Active Pharmaceutical Ingredients CDMO Market, by Workflow, 2020-2030

10.1.1.  Clinical

10.1.1.1.      Market Revenue and Forecast (2016-2030)

10.1.2.  Commercial

10.1.2.1.      Market Revenue and Forecast (2016-2030)

Chapter 11.      Global Active Pharmaceutical Ingredients CDMO Market, By Application

11.1.        Active Pharmaceutical Ingredients CDMO Market, by Application, 2020-2030

11.1.1.  Oncology

11.1.1.1.      Market Revenue and Forecast (2016-2030)

11.1.2.  Hormonal

11.1.2.1.      Market Revenue and Forecast (2016-2030)

11.1.3.  Glaucoma

11.1.3.1.      Market Revenue and Forecast (2016-2030)

11.1.4.  Cardiovascular

11.1.4.1.      Market Revenue and Forecast (2016-2030)

11.1.5.  Diabetes

11.1.5.1.      Market Revenue and Forecast (2016-2030)

11.1.6.  Others

11.1.6.1.      Market Revenue and Forecast (2016-2030)

Chapter 12.      Global Active Pharmaceutical Ingredients CDMO  Market, Regional Estimates and Trend Forecast

12.1.        North America

12.1.1.  Market Revenue and Forecast, by Product (2016-2030)

12.1.2.  Market Revenue and Forecast, by Synthesis (2016-2030)

12.1.3.  Market Revenue and Forecast, by Drug (2016-2030)

12.1.4.  Market Revenue and Forecast, by Workflow (2016-2030)

12.1.5.  Market Revenue and Forecast, by Application (2016-2030)

12.1.6.  U.S.

12.1.6.1.      Market Revenue and Forecast, by Product (2016-2030)

12.1.6.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.1.6.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.1.6.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.1.6.5.      Market Revenue and Forecast, by Application (2016-2030)

12.1.7.  Rest of North America

12.1.7.1.      Market Revenue and Forecast, by Product (2016-2030)

12.1.7.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.1.7.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.1.7.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.1.7.5.      Market Revenue and Forecast, by Application (2016-2030)

12.2.        Europe

12.2.1.  Market Revenue and Forecast, by Product (2016-2030)

12.2.2.  Market Revenue and Forecast, by Synthesis (2016-2030)

12.2.3.  Market Revenue and Forecast, by Drug (2016-2030)

12.2.4.  Market Revenue and Forecast, by Workflow (2016-2030)

12.2.5.  Market Revenue and Forecast, by Application (2016-2030)

12.2.6.  UK

12.2.6.1.      Market Revenue and Forecast, by Product (2016-2030)

12.2.6.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.2.6.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.2.6.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.2.6.5.      Market Revenue and Forecast, by Application (2016-2030)

12.2.7.  Germany

12.2.7.1.      Market Revenue and Forecast, by Product (2016-2030)

12.2.7.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.2.7.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.2.7.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.2.7.5.      Market Revenue and Forecast, by Application (2016-2030)

12.2.8.  France

12.2.8.1.      Market Revenue and Forecast, by Product (2016-2030)

12.2.8.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.2.8.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.2.8.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.2.8.5.      Market Revenue and Forecast, by Application (2016-2030)

12.2.9.  Rest of Europe

12.2.9.1.      Market Revenue and Forecast, by Product (2016-2030)

12.2.9.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.2.9.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.2.9.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.2.9.5.      Market Revenue and Forecast, by Application (2016-2030)

12.3.        APAC

12.3.1.  Market Revenue and Forecast, by Product (2016-2030)

12.3.2.  Market Revenue and Forecast, by Synthesis (2016-2030)

12.3.3.  Market Revenue and Forecast, by Drug (2016-2030)

12.3.4.  Market Revenue and Forecast, by Workflow (2016-2030)

12.3.5.  Market Revenue and Forecast, by Application (2016-2030)

12.3.6.  India

12.3.6.1.      Market Revenue and Forecast, by Product (2016-2030)

12.3.6.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.3.6.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.3.6.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.3.6.5.      Market Revenue and Forecast, by Application (2016-2030)

12.3.7.  China

12.3.7.1.      Market Revenue and Forecast, by Product (2016-2030)

12.3.7.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.3.7.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.3.7.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.3.7.5.      Market Revenue and Forecast, by Application (2016-2030)

12.3.8.  Japan

12.3.8.1.      Market Revenue and Forecast, by Product (2016-2030)

12.3.8.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.3.8.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.3.8.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.3.8.5.      Market Revenue and Forecast, by Application (2016-2030)

12.3.9.  Rest of APAC

12.3.9.1.      Market Revenue and Forecast, by Product (2016-2030)

12.3.9.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.3.9.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.3.9.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.3.9.5.      Market Revenue and Forecast, by Application (2016-2030)

12.4.        MEA

12.4.1.  Market Revenue and Forecast, by Product (2016-2030)

12.4.2.  Market Revenue and Forecast, by Synthesis (2016-2030)

12.4.3.  Market Revenue and Forecast, by Drug (2016-2030)

12.4.4.  Market Revenue and Forecast, by Workflow (2016-2030)

12.4.5.  Market Revenue and Forecast, by Application (2016-2030)

12.4.6.  GCC

12.4.6.1.      Market Revenue and Forecast, by Product (2016-2030)

12.4.6.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.4.6.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.4.6.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.4.6.5.      Market Revenue and Forecast, by Application (2016-2030)

12.4.7.  North Africa

12.4.7.1.      Market Revenue and Forecast, by Product (2016-2030)

12.4.7.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.4.7.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.4.7.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.4.7.5.      Market Revenue and Forecast, by Application (2016-2030)

12.4.8.  South Africa

12.4.8.1.      Market Revenue and Forecast, by Product (2016-2030)

12.4.8.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.4.8.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.4.8.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.4.8.5.      Market Revenue and Forecast, by Application (2016-2030)

12.4.9.  Rest of MEA

12.4.9.1.      Market Revenue and Forecast, by Product (2016-2030)

12.4.9.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.4.9.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.4.9.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.4.9.5.      Market Revenue and Forecast, by Application (2016-2030)

12.5.        Latin America

12.5.1.  Market Revenue and Forecast, by Product (2016-2030)

12.5.2.  Market Revenue and Forecast, by Synthesis (2016-2030)

12.5.3.  Market Revenue and Forecast, by Drug (2016-2030)

12.5.4.  Market Revenue and Forecast, by Workflow (2016-2030)

12.5.5.  Market Revenue and Forecast, by Application (2016-2030)

12.5.6.  Brazil

12.5.6.1.      Market Revenue and Forecast, by Product (2016-2030)

12.5.6.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.5.6.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.5.6.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.5.6.5.      Market Revenue and Forecast, by Application (2016-2030)

12.5.7.  Rest of LATAM

12.5.7.1.      Market Revenue and Forecast, by Product (2016-2030)

12.5.7.2.      Market Revenue and Forecast, by Synthesis (2016-2030)

12.5.7.3.      Market Revenue and Forecast, by Drug (2016-2030)

12.5.7.4.      Market Revenue and Forecast, by Workflow (2016-2030)

12.5.7.5.      Market Revenue and Forecast, by Application (2016-2030)

Chapter 13.  Company Profiles

13.1.              Cambrex

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.              Recipharm

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.              Thermo Fisher Pantheon

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.              Corden Pharma

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.              Samsung Biologics

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.              Lonza

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.              Catalent

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.              Siegfried

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.              Piramal Pharma Solutions

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.           Boehringer Ingelheim

13.10.1.               Company Overview

13.10.2.               Product Offerings

13.10.3.               Financial Performance

13.10.4.               Recent Initiatives

Chapter 14.  Research Methodology

14.1.              Primary Research

14.2.              Secondary Research

14.3.              Assumptions

Chapter 15.  Appendix

15.1.              About Us

Glossary of Terms